Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol. Pharmacokinetics and Pharmacodynamics in Healthy Adults : A Randomized Clinical Trial C. Austin Zamarripa, PhD; Tory R. Spindle, PhD; Renuka Surujunarain; Elise M. Weerts, PhD; Sumit Bansal, PhD; Jashvant D. Unadkat, PhD; Mary F. Paine, PhD; Ryan Vandrey, PhD Jama Network Open, 2023, 6, (2), e2254752, 1-15. doi : 10.1001/jamanetworkopen.2022.54752 Key Points Question : Are there acute pharmacokinetic or pharmacodynamic differences between oral ingestion of a Δ9-tetrahydrocannabinol (Δ9-THC)- dominant cannabis extract compared with a cannabidiol (CBD)-dominant extract at the same Δ9-THC dose (20 mg) in healthy adults who use cannabis infrequently? Findings : In this randomized clinical trial including 18 [...]
Lire la suiteEffect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters Jose´A. Crippa, Luiz C. Pereira Junior, Livia C. Pereira, Patricia M. Zimmermann, Liberato Brum Junior, Leticia M. Rechia, Isabella Dias, Jaime E. Hallak, Alline C. Campos, Francisco S. Guimaraes, Regina H. Queiroz, Antonio W. Zuardi Brazilian Journal of Psychiatry, 2021, 1-6. Doi : 10.1590/1516-4446-2020-1684 Objective : To compare plasma concentrations of cannabidiol (CBD) following oral administration of two formulations of the drug (powder and dissolved in oil), and to evaluate the effects of these distinct formulations on responses to emotional stimuli in healthy human volunteers. Methods [...]
Lire la suitePharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects Friederike Holze, Urs Duthaler, Patrick Vizeli, Felix Müller, Stefan Borgwardt, Matthias E. Liechti British Journal of Clinical Pharmacology, March 2019 Doi : 10.1111/bcp.13918 Aims : The aim of the present study was to characterize the pharmacokinetics and exposure–subjective response relationship of a novel oral solution of lysergic acid diethylamide (LSD) that was developed for clinical use in research and patients. Method : LSD (100 μg) was administered in 27 healthy subjects using a placebocontrolled, double‐blind, cross‐over design. Plasma levels of LSD, nor‐LSD, and 2‐ oxo‐3‐hydroxy‐LSD (O‐H‐LSD) and subjective drug effects were assessed [...]
Lire la suiteNonlinear Disposition and Metabolic Interactions of Cannabidiol Through CYP3A Inhibition In Vivo in Rats Michiru Nagao, Yukako Nakano, Masataka Tajima, Erika Sugiyama, Vilasinee Hirunpanich Sato, Makoto Inada, and Hitoshi Sato Cannabis and Cannabinoid Research, 2020, Volume X, Number X, 1-8. DOI: 10.1089/can.2019.0098 Abstract Introduction : Cannabidiol (CBD) is known to affect the pharmacokinetics of other drugs through metabolic inhibition of CYP2C19 and CYP3A4. However, there is a lack of in vivo evidence for such drug interactions. Therefore, we investigated the saturability of CBD metabolism and CBD-drug interactions through inhibition of CYP3A in vivo. Materials and Methods : A nanoemulsion formulation of CBD (CBD-NE) was orally administered to [...]
Lire la suiteA Systematic Review on the Pharmacokinetics of Cannabidiol in Humans Sophie A. Millar, Nicole L. Stone, Andrew S. Yates and Saoirse E. O’Sullivan Frontiers in Pharmacology, 26 November 2018 https://doi.org/10.3389/fphar.2018.01365 Background : Cannabidiol is being pursued as a therapeutic treatment for multiple conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but literature in humans is not sufficient. The aim of this review was to collate published data in this area. Methods : A systematic search of PubMed and EMBASE (including MEDLINE) was conducted to retrieve all articles reporting pharmacokinetic data of CBD in humans. Results : Of 792 articles retireved, 24 included [...]
Lire la suite